Genta Can #39;t Catch a Break Genta (GNTA:Nasdaq - news - research) is never boring! Monday night, the company announced that its phase III Genasense study in chronic lymphocytic leukemia (CLL) met its primary endpoint, which was tumor shrinkage. 
What label best describes this news article? 